INTRODUCTION
Although modern synthetic chemistry has made great progress only one de novo compound, initiated by combinatorial chemistry, has been approved as a drug (the antitumor compound known as sorafenib from Bayer, approved by the FDA in 2005), in over 25 years from 1981 to 2006 (1) . According to a report from the World Health Organization (WHO), between 70% and 95% of people in developing countries rely on traditional medicine as their primary source of medication, suggesting that new drugs might be discovered by paying more attention to learning from Nature (2) .
There are two ways to learn from Nature. One way is to learn from natural products, the results of Nature's creation. People have been doing this for many years. For more than a century, natural products, including marine products and phytochemicals, have been extracted from natural organisms and screened against biological targets. However, there are major challenges to this approach: more and more natural organisms are becoming endangered and utilizing and modifying their natural products can cause ecological problems. Thus, when a natural product is officially approved as a drug or as a nutritional supplement, the organisms that produce the product are potentially at risk. Globalization and worldwide environmental changes exacerbate the situation. Many traditional Chinese medicines (TCM) are losing their medical functions due to the shortage of authentic traditional Chinese herbs. For example, TCM herbs usually depend on the locations where they are cropped; however, there is constant deterioration to the ecological systems of these locations. Moreover, chemically reproducing natural products is still difficult and costly. We have to seek new ways of producing natural products without provoking ecological crises. _________________________________________ Another way is to learn from the processes that Nature uses to create natural products. Most natural products are made in cells with non-extreme conditions (aqueous solution, neutral pH, room temperature, and normal atmospheric pressure). However, the cells can make natural products from a few simpler endogenous molecules efficiently. The secret is that the cells use enzymes as catalysts, and these enzymes can be regulated through physical conditions, other enzymes, ions, and small molecules. If these processes can be deciphered and mimicked, natural products or quasi-natural products can be made more efficiently without ecological consequences.
In this paper, we focus on deciphering how Nature reproduces and creates natural products. We started by identifying chemoyls(3) that Nature uses to make its bioactive compounds. Then we tried to identify the rules for combining these chemoyls to make organic compounds for bioactivities. Finally, we applied these rules to make a quasi-natural product library for the identification of drug leads. The rules of combining chemoyls are not so simple as to be represented in a "chemoyl periodic table". Instead, the rules have to be represented in networks.
METHODS

Defining Chemoyls and Biological Building Blocks
Drug design should be a process that assembles a number of molecular components to make a biofunctional molecule. Therefore, the first question for drug design is what is a molecular component? As shown in Figure 1 , a natural product (A) can be disassembled into a number of simpler structural fragments, chemoyls (B). A chemoyl is not a molecular entity; it is a molecular fragment. An endogenous molecule that can contribute a chemoyl to a target molecule (natural product) in an enzyme-catalyzed chemical reaction is a natural product building block ( Figure 1C ).
Distinguishing Chemoyls and Building Blocks
The concept of molecular chemical parts has been proposed for many years. For example, the "isoprene rule" was first recognized by Wallach in the 19 th century(4), and was extended into the "biogenetic isoprene rule" by Ruzicka sixty-six years later (5) . Isoprene is a typical molecular part for many natural product molecules. Today, there are about ten natural product molecular components recognized by natural product chemists (6) . To be concise, we term the molecular components as shown in Figure 1B as chemoyls, and term the molecule containing a chemoyl with an activation group or groups as a building block (Fig. 1C) .
In chemistry, a building block means a compound that can be used to make other novel compounds. In biochemistry, a building block is a molecular entity that exists in a life system, and is an endogenous molecule (3). A biological building block can be used to make many different natural product molecules. Therefore, it is not obvious which building blocks have been used to build a natural product molecule. Moreover, there are many ways to disassemble a natural product molecule into chemoyls because there are many ways to make a natural product molecule in Nature.
Therefore, drug design requires the identification of molecular components to construct a natural product like molecular library, screening the library against drug target(s), seeking optimized synthetic routes and building blocks to make promising hits, converting the hits to leads, and improving the pharmacophore properties of the leads. 
Seeking Chemoyls and Corresponding Building Blocks
Although, a chemoyl cannot be easily recognized by simply inspecting a natural product molecular structure, it can be derived from natural product molecular structures by systematic analyses. The "isoprene rule" is a good example.
To construct a quasi-natural product library, we have to discover rules to combine chemoyls. These rules can be revealed by systematically analyzing the partnerships of chemoyls in a natural product database, such as the TCM chemical structure database (7) .
Based upon the discussion above, rational drug design requires the following elements: (1) drug targets; (2) interaction models of the target and drug; (3) chemoyls and their combinatorial rules; and (4) the biological or chemical building blocks related to the chemoyls. We consider both biological and chemical building blocks, because we want to employ both biological and chemical techniques to synthesize drug or drug like molecules from chemoyls.
Biological building blocks are organic compounds or metabolites that are present in many organisms or cells; they are utilized in other natural products as subunits. In short, building blocks are precursors of other natural products.
It is easy to recognize that proteinogenic amino acids, or the five nucleoside bases (including the purines A and G and the pyrimidines C, T and U), ribose, and deoxyribose are biological building blocks, because they are precursors to proteins or nucleic acids (DNA and RNA) respectively.
Other biological building blocks, such as short half-life endogenous compounds (e.g., ornithine, homoserine, isoprene derivatives, shikimic acid, pyruvic acid, etc.) are important as precursors to the above-mentioned building blocks (e.g., proteinogenic amino acids). However, they are not synthesized with well-known peptide polymerases. They are assembled through non-ribosomal peptide-synthetase (NRPS) enzymes. These building blocks are structurally more diverse (i.e., they are not necessarily amino acids), and have to be derived from natural product databases and other references by data mining approaches.
The annotated TCM chemical structure database (ATCMD)(7) is a natural product database that contains TCM usage information, structural data and bioassay results discussed in the Encyclopedia of TCM. It is an integrated achievement of a long-term TCM research project by authors at the Chinese Academy of Sciences seeking to derive chemoyls from ATCMD.
Natural products (excluding proteins, DNA or RNA) are typically divided into primary metabolites (molecules that are directly involved in the regulation of life systems, e.g., growth, development, and reproduction) and secondary metabolites (molecules that are not directly involved in the regulation of life systems, and often play roles in defense against environmental stresses). Some secondary metabolites are precursors to the primary metabolites.
RESULTS
Currently 129 chemoyls have been derived from ATCMD and other references (6, 8) . These chemoyls are divided into 15 classes. Each chemoyl class associates with a number of bioactivities related to TCM herbs (as shown in Figure 2 ). The terpenene, alkaloid, and flavone classes are associated with the highest number of bioactivities; the saccharide, amino acid, steroid, lignin, quinone, coumarin, and tannin classes are associated with a medium number of bioactivities; and the benzofuran, stilbene, chromene, nucleoside, and polyene classes are associated with the lowest number of bioactivities. This is understandable because terpenenes, alkaloids, and flavones/ flavonols are the largest and most diverse groups of plant secondary compounds. Terpenes are common in most plants and fungi, but they rarely accumulate in bacteria. More than 15,000 terpenoids are discovered. They generally occur free, or derivatized as esters and glycosides, or attached to proteins. Steroids in mammals are products of terpenoid metabolism (9) . More than 12,000 alkaloids have been discovered (10) . Flavonols and flavones are produced widely in plants and are mainly concentrated in the outer tissues. Flavonols act as antioxidants and protect ascorbic acid from auto-oxidation (11). Benzofurans, stilbenes, chromenes, nucleosides, and polyenes without annotated bioactivities in the current version of the database may have lower occurrences in plants, or exhibit stability problems. Further investigations are required.
In nature, these chemoyls are covalently combined to form new molecular moieties, which occur for specific stress resistance purposes. The moieties, however, may be used for other biological purposes. For example, a natural product was produced to be a plant antibiotic; however, it can also be used as an anti-aging agent. Therefore, a chemoyl group can be associated with many bioactivities, as shown in Figure 3 . In Figure 3 , larger square nodes represent chemoyl groups; smaller circles represent associated bioactivities (as discovered in TCM); smaller rectangles represent combined chemoyls, composed of simpler chemoyls, among larger square nodes. The codes in the smaller circles represent the individual bioactivities described in reference (7) . This figure demonstrates that smaller chemoyls tend to associate with a larger number of bioactivities. When two chemoyls are combined, the number of associated bioactivities is significantly reduced. This is because specificity increases when a molecule is made from more than one chemoyl.
The chemoyl combination networks can be formed based upon the combinations of 3, 4, and 5 chemoyls, which generate maps with enhanced complexity as shown in Figures 4 A to C. These networks indicate that molecules generated by higher numbers of chemoyls will have fewer activities. For example, based on mining ATCMD data, combining quinone, tannin, and polyene can generate only one activity (A00819); similarly, combining quinone, tannin, nucleoside, and stilbene can generate only one activity (A0134).
When chemoyls are combined, the new molecule is larger in size, more rigid in shape, and has enhanced target specificity. Therefore, the new molecule has a smaller number of associated activities but individual activities are frequently enhanced. This outcome is frequently observed in the results from mining ATCMD structure data (as shown in Figure 5 ).
In Figure 5 , the size of a pie-chart represents the number of bioactivities for the associated chemoyl or combination of chemoyls. Here, three chemoyls, benzofuran, flavone, and stilbene, are associated with more bioactivities than their combinations. The colors in the pie-chart stand for distinct bioactivities. For example, the major bioactivities for stilbene derivatives are anti-oxidization, anti-cancer, and anti-bacterial. Combining stilbene chemoyls and benzofurans produce new molecules that have fewer bioactivity types. Furthermore, combining the three chemoyls in Figure 5 produces new molecules with reduced spectra of bioactivity.
The 15 chemoyl classes form a chemoyl-type activity network which demonstrates the relations among fifteen chemoyl-types. Figure 6 indicates that steroids (7) and terpenes (15) are more frequently covalently combined to produce the natural products that have the most diverse bioactivities in TCM. Polyene (13) is isolated from the network; it is not commonly combined with other chemoyls. Flavones ( 1 ), steroids ( 7 ), alkaloids ( 14 ) and terpenes ( 15 ) are most frequently (indicated by darker lines) present in natural products simultaneously, so as to exhibit more bioactivities.
In case of triple chemoyl-type combinations, we have created tri-chemoyl-type activity networks as shown in Figure 7 . In this network, an edge stands for three chemoyl-types covalently combined together with amino acid scaffolds.
Chemoyl-type activity networks are both statistic and dynamic. The topology of a network depends on the threshold number of new bioactivities for new chemoyls produced from parent chemoyls. The networks indicate that chemoyl types can form more or less new chemical entities that exhibit a number of bioactivities. Consequently, the rules of chemoyl combination are determined by biological targets per se.
A note on the screening of the TCM database for lead compounds using computational methods
In addition to standard cell and/or animal-based drug target analysis, virtual screening provides an alternative strategy for the identification of lead compounds and would appear to be suitable for the analyses of the TCM biochemome project. Successful examples include the report of Giacomini and colleagues at UCSF who identified four large-neutral amino acid transporter 1 (LAT-1) ligands by virtual screening (12) and Leung and colleagues who identified inhibitors of tumor necrosis factor-α from a library of marketed drugs using virtual screening methods (13) . For a review of successful cases of drug repositioning by virtual screening see Ref. (14) .
CONCLUSIONS
By mining ATCMD data, we have generated three types of chemoyl-bioactivity networks. These networks represent the rules of chemoyl combination. Our studies reveal that biochemomes do indeed exist in the form of chemical building blocks. The rules governing chemoyl assemblies are in the form of networks, not in the form of a rectangular table. The networks are dynamic, and change with the evolution of life systems.
Based upon the rules of chemoyl combination and related bioactivities, quasi-natural product libraries can be constructed from a set of biochemoyls for specified bioactivities and virtual screening can be performed against drug targets using a number of computational tools (15) (16) (17) (18) (19) . A consequent challenge is to develop feasible synthetic technologies to make the libraries. A number of technologies have been developed for chemical syntheses (20) , biological syntheses (21) (22) (23) , and biomimetic syntheses (24) (25) (26) (27) (28) (29) .
We are presently engaged in identifying natural biochemoyls and the natural assembly rules of the biochemome by data-mining TCM and other natural product databases. Biochemomics is still young; there are many things to be done. Figure 7A means that an amino acid, a stilbene, and a saccharide can form new chemoyl types that exhibit more than 10 bioactivities; edge ○ 1 -○ 5 in Figure 7B means that an amino acid, a flavone, and a coumarin can form new chemoyl types that exhibit more than 20 bioactivities; and edge ○ 11 -○ 15 in Figure 7C means that an amino acid, a saccharide, and a terpene can form new chemoyl types that exhibit more than 30 bioactivities. C, D, and E: an edge stands for the new chemoyl types formed from steroid scaffolds and two other chemoyl types, and which exhibit multiple (>10) activities.
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